We postulate that monotherapeutic schemes blocking HuR functions should be avoided in CRC arising in the context of IBD, where anti-cytokine therapies are also envisaged for applicability (e.g., anti-IL6). Here, ELAVL1 is linked to colorectal carcinoma.